Wolf et al (2000) have investigated a complementary approach in which wild-type p53 is reintroduced into tumour cells using adenovirus ADP53 in an attempt to restore chemosensitivity and promote apoptosis. Preliminary results from the Phase I study in 14 evaluable patients demonstrate that i.p. ADP53 is feasible and well tolerated (Wolf et al, 2000). This evidence concerns the gene TP53 and neoplasm.